Bioloomics leverages activity-guided antibody library screening through Synthetic Biology, AI, Imaging, and Robotics to build a therapeutic pipeline of anti-cancer therapies.

Bioloomics

BioLoomics is a preclinical stage biotechnology company leveraging directed evolution of antibodies in human cells to create ADCs with improved internalization and trafficking. Our proprietary tech combines single-cell bioassay engineering, robotics, and ML. 
#synbio #directedevolution #antibodies #ADCs

BioLoomics

BioLoomics is all about evolution...even our lab space. 
We were once one bench at CU Boulder, then in a founder's garage, then in two separate FLEX spaces. Along the way, we have collected the do's and don't for a successful lab design. 

We recently began building a new HQ in the West Flatiron Park where we will bring together our operation in a brand new state of the art lab. 

Special thanks to Patrick Brady, CCIM, Sharon Wilhelm, and Craig Lemle at Savills for helping us navigate the real estate ecosystem in Boulder, CO, to our very own Nicole Beach for managing and heading up this lab build out, and to our architect Ethan Hampton.  

This is the blank canvas today that will morph into a BSL1 and BSL2 antibody drug conjugate optimization lab:

We Welcome Kurt Gish as the Chief Scientific Officer (CSO) of BioLoomics. 

👉 Kurt is an ADC Expert
👉 He Has Successfully Taken ADC Programs to The Clinic
👉 He is an Inspiring Person & Great Leader

We Are Excited to Have You On Board!

#ADCs, #Biotech

https://lnkd.in/ga6443xC

We're #hiring a new Scientist I -- Protein Expression & Purification in Boulder, Colorado. Apply today or share this post with your network.

BioLoomics welcomes Dr. Chris Bahl as a scientific advisor! 

Dr. Bahl is the President, CSO, and Co-founder of AI Proteins. Dr. Bahl pioneered the ability to computationally design miniproteins de novo as a postdoctoral fellow with Dr. David Baker at the University of Washington’s Institute for Protein Design in Seattle. Following his post-Doc, he joined the Institute for Protein Innovation in Boston as one of the founding faculty members, with co-appointments at Boston Children’s Hospital and Harvard Medical School. Dr. Bahl is an expert in the state-of-the-art computational tools for protein design, which BioLoomics is leveraging to climb the fitness landscape across multiple activities for antibody chimeras. We are super excited to work with you!

Learn more about AI Proteins at aiproteins.bio
Hear Chris’s Ted talk at https://lnkd.in/giXDPkjN
Learn more about BioLoomics at www.bioloomics.com

#Biologics #ADCs #TargetedProteinDegradation

BioLoomics welcomes Dr. Jeanne Stachowiak as a scientific advisor! 

Dr. Stachowiak is a jointly appointed professor of Chemical Engineering and the Department of Biomedical Engineering at the University of Texas at Austin. Her research into how proteins and lipids interact at the cell membrane has highlighted the power of biophysical activities like phase separation in endocytosis, receptor sorting, and membrane curvature sensing/generation. Dr. Stachowiak has unique insights into the protein design principles that underly membrane interaction that will aid our development of antibodies with programmable trafficking to the lysosome. We are super excited to work with you!

Learn more about Jeanne and her research at www.stachowiaklab.org
Learn more about BioLoomics at www.BioLoomics.com

#Biologics, #ADCs, #TargetedProteinDegradation

Thank You Calvin Chen at WuXi Biologics for inducting BioLoomics into the Enable the Molecule Program. 

This innovative program will accelerate our ability to generate and optimize candidate antibodies through fast paced Phage Display, Cell & Animal Studies, Etc. We are excited to work together on this journey to bring novel antibody degraders and more to unmet areas of therapeutic need!

msh id	COM:BIOLOOMICS
symbol	-
name	Bioloomics
homepage url	https://www.bioloomics.com
country	US
sector	Healthcare & Health Services
industry	Biotechnology
market	PRIVATE
employee count	17
crunchbase url	-
linkedin url	https://www.linkedin.com/company/bioloomics
founders	-

market cap	-
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	-
growth cost of revenue	-
growth depreciation and amortization	-
growth ebitda	-
growth ebitda ratio	-
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-
growth gross profit	-
growth gross profit ratio	-

COM:BIOLOOMICS

Bioloomics

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	-
cost of revenue	-
depreciation and amortization	-
ebitda	-
ebitda ratio	-
eps	-
eps diluted	-
operating expenses	-
operating income	-
operating income ratio	-

accounts receivables	-
capital expenditure	-
cash at beginning of period	-
cash at end of period	-
inventory	-
working capital ttm	-

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-